Published in Mol Cell Proteomics on December 26, 2012
The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles (2014) 1.92
Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics (2014) 0.87
Myeloma cells can corrupt senescent mesenchymal stromal cells and impair their anti-tumor activity. Oncotarget (2015) 0.79
Use of composite protein database including search result sequences for mass spectrometric analysis of cell secretome. PLoS One (2015) 0.78
Elucidation of the CHO Super-Ome (CHO-SO) by Proteoinformatics. J Proteome Res (2015) 0.78
Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. Mol Cell Proteomics (2015) 0.77
Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype. Biomed Res Int (2015) 0.76
In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget (2016) 0.75
Cancer Secretome May Influence BSP and DSP Expression in Human Salivary Gland Cells. J Histochem Cytochem (2016) 0.75
Extracellular Protein Phosphorylation, the Neglected Side of the Modification. Mol Cell Proteomics (2016) 0.75
An Optimized Approach to Recover Secreted Proteins from Fibroblast Conditioned-Media for Secretomic Analysis. Front Cell Neurosci (2016) 0.75
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res (2010) 18.73
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol (2010) 11.05
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem (1986) 6.03
Active caspase-1 is a regulator of unconventional protein secretion. Cell (2008) 5.89
Emerging molecular markers of cancer. Nat Rev Cancer (2002) 5.03
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep (2002) 4.76
The cancer biomarker problem. Nature (2008) 4.64
Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol (2008) 3.17
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol (2008) 2.80
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics (2009) 2.08
Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics (2010) 2.04
The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signal (2012) 1.81
A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. Mol Cell Proteomics (2002) 1.78
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One (2008) 1.72
Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics (2004) 1.57
Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. Proc Natl Acad Sci U S A (2005) 1.55
Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer (2011) 1.54
Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol (2012) 1.45
Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res (2010) 1.42
Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics (2005) 1.32
Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov (2009) 1.21
Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem (1999) 1.20
The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells. FASEB J (2007) 1.14
Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol (2009) 1.12
Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-x(L) inhibition. PLoS One (2011) 1.07
Secretome-based proteomic profiling of Ras-transformed MDCK cells reveals extracellular modulators of epithelial-mesenchymal transition. J Proteome Res (2009) 0.99
Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Res (2009) 0.97
Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fibronectin and promotes tumor progression. Am J Pathol (2011) 0.86
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med (2012) 9.17
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst (2007) 4.03
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell (2010) 3.69
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (2006) 3.17
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 3.07
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov (2014) 2.79
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol (2009) 2.37
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res (2004) 2.04
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med (2012) 2.02
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med (2013) 1.98
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med (2012) 1.93
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol (2007) 1.93
Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer (2004) 1.92
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res (2010) 1.92
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res (2014) 1.86
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med (2013) 1.82
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res (2006) 1.70
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol (2010) 1.69
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res (2013) 1.68
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J (2006) 1.65
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res (2012) 1.65
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.60
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res (2002) 1.57
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol (2009) 1.54
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol (2006) 1.49
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol (2004) 1.49
Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 1.40
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
p95HER2 and breast cancer. Cancer Res (2011) 1.38
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol (2008) 1.37
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 1.36
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist (2013) 1.35
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol (2006) 1.34
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol (2009) 1.33
Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol (2012) 1.29
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol (2010) 1.23
Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol Cell Biol (2006) 1.21
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res (2011) 1.18
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol (2008) 1.16
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest (2013) 1.16
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res (2013) 1.14
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2011) 1.14
Targeted therapies in breast cancer: where are we now? Eur J Cancer (2008) 1.14
Keeping faith with trial volunteers. Nature (2007) 1.13
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer (2013) 1.11
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer (2002) 1.10
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res (2008) 1.08
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther (2010) 1.07
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res (2005) 1.07
Impact of genomics on personalized cancer medicine. Clin Cancer Res (2012) 1.06
Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation? Clin Cancer Res (2009) 1.05
Treating cancer's kinase 'addiction'. Nat Med (2004) 1.05
Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res (2013) 1.04
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res (2013) 1.02
A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res (2010) 1.02
Multiple insect resistance in transgenic tomato plants over-expressing two families of plant proteinase inhibitors. Plant Mol Biol (2005) 0.99
Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Res (2009) 0.97
A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antiviral Res (2013) 0.96
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res (2014) 0.95
Molecular approach to breast cancer treatment. Semin Oncol (2004) 0.95
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer (2008) 0.94
Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nat Rev Clin Oncol (2011) 0.92
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov (2013) 0.91
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther (2011) 0.91
Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res (2013) 0.91
Functional screening of serine protease inhibitors in the medical leech Hirudo medicinalis monitored by intensity fading MALDI-TOF MS. Mol Cell Proteomics (2005) 0.90